Bericht

Patent analysis for medicines and biotherapeutics in trials to treat COVID-19

This report provides an analysis of patents covering medicines in trials to treat COVID-19. The aim of the report is to support national patent offices and interested parties in developing countries with information that can serve as guidance for the examination of the claims contained in relevant patents or patent applications. The medicines considered for the patent analysis in this report are remdesivir, ruxolitinib, favipiravir, molnupiravir and nirmatrelvir, and the biotherapeutics tocilizumab, siltuximab and sarilumab.

Language
Englisch

Bibliographic citation
Series: Research Paper ; No. 153

Classification
Sozialwissenschaften, Soziologie, Anthropologie
Subject
Access to Medicines
Affordable Medicines
Biotherapeutics
Coronavirus
COVID-19
Favipiravir
Global Health
Health
Intellectual Property
Molnupiravir
Nirmatrelvir
Pandemic
Patent
Patent Offices
Public Health
Remdesivir
Ruxolitinib
Sarilumab
Siltuximab
Tocilizumab

Event
Geistige Schöpfung
(who)
Ravi, Srividya
Event
Veröffentlichung
(who)
South Centre
(where)
Geneva
(when)
2022

Handle
Last update
10.03.2025, 11:44 AM CET

Data provider

This object is provided by:
ZBW - Deutsche Zentralbibliothek für Wirtschaftswissenschaften - Leibniz-Informationszentrum Wirtschaft. If you have any questions about the object, please contact the data provider.

Object type

  • Bericht

Associated

  • Ravi, Srividya
  • South Centre

Time of origin

  • 2022

Other Objects (12)